Mark Yarchoan
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Hepatology 35
- Hepatocellular Carcinoma Treatment and Prognosis 33
- Oncology 93
- Cancer Immunotherapy and Biomarkers 66
- Pancreatic and Hepatic Oncology Research 25
- CAR-T cell therapy research 14
- Co-authors
- Elizabeth M. JaffeeDaniel A. LaheruSolange PetersCharles SwantonSergio A. QuezadaAlbrecht StenzingerTimothy A. ChanBurles A. Johnson
- Journals
- Journal of Clinical Oncology (28 papers)Cancer Research (9 papers)JCI Insight (9 papers)Hepatology (7 papers)Clinical Cancer Research (6 papers)
- Partner nations
- United StatesSpainNew Zealand
In The Last Decade
Mark Yarchoan
135 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Oncology 4.3k
- Hepatology 1.1k
- Cancer Research 1.5k
- Immunology 2.2k
- Pulmonary and Respiratory Medicine 2.1k
Countries citing papers authored by Mark Yarchoan
This map shows the geographic impact of Mark Yarchoan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yarchoan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yarchoan more than expected).
Fields of papers citing papers by Mark Yarchoan
This network shows the impact of papers produced by Mark Yarchoan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yarchoan. The network helps show where Mark Yarchoan may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Yarchoan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma Hit paper breakdown → | 2024 | 162 |
| 3 | 2024 | 3 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 3 | |
| 6 | 2024 | 2 | |
| 7 | 2024 | 13 | |
| 8 | 2023 | 14 | |
| 9 | 2022 | 10 | |
| 10 | 2022 | 18 | |
| 11 | 2022 | 32 | |
| 12 | 2022 | 13 | |
| 13 | 2021 | 17 | |
| 14 | 2020 | 69 | |
| 15 | 2019 | 180 | |
| 16 | 2019 | 92 | |
| 17 | 2019 | 20 | |
| 18 | PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers Hit paper breakdown → | 2019 | 386 |
| 19 | 2019 | 68 | |
| 20 | 2019 | 49 |
About Mark Yarchoan
Mark Yarchoan is a scholar working on Hepatology, Oncology, Cancer Research, Immunology and Pulmonary and Respiratory Medicine, having authored 151 papers that have together received 8.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (66 papers), Hepatocellular Carcinoma Treatment and Prognosis (33 papers), Immunotherapy and Immune Responses (26 papers), Pancreatic and Hepatic Oncology Research (25 papers), Cancer Genomics and Diagnostics (22 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers), CAR-T cell therapy research (14 papers) and Ferroptosis and cancer prognosis (8 papers). The work is most often cited by research in Oncology (4.3k citations), Hepatology (1.1k citations), Cancer Research (1.5k citations), Immunology (2.2k citations) and Pulmonary and Respiratory Medicine (2.1k citations). Mark Yarchoan has collaborated with scholars based in United States, Spain and New Zealand. Frequent co-authors include Elizabeth M. Jaffee, Daniel A. Laheru, Solange Peters, Charles Swanton, Sergio A. Quezada, Albrecht Stenzinger, Timothy A. Chan, Burles A. Johnson, Eric R. Lutz and Steven E. Arnold. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, JCI Insight, Hepatology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.